FDA Issues Draft Guidance for Gene Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 8 hours ago
0mins
The U.S. Food and Drug Administration said it has issued draft guidance to help developers bring promising gene therapies to patients more efficiently by making greater use of existing scientific and regulatory knowledge. When finalized, the guidance will outline how sponsors can use publicly available information and established platform knowledge, including chemistry, manufacturing and controls data, nonclinical study results and clinical information, to streamline regulatory submissions for human gene therapy products that use genome editing in human somatic cells. "Today's action reflects the FDA's commitment to get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options," said Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research. "By providing information on how companies may build on what is already known we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on.Ultimately, this is about making sure that the promise of gene therapy reaches the patients who need it most, as quickly and safely as possible." This draft guidance supports the development of a wide range of cell and gene therapy products, including those that use genome editing, and is part of a broader set of complementary FDA actions in this area. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Biotech stocks include Replimune (REPL), Moderna (MRNA), Sarepta (SRPT), Xencor (XNCR), PTC Therapeutics (PTCT), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Design Therapeutics (DSGN), Ultragenyx (RARE), Dyne Therapeutics (DYN), Wave Life Sciences (WVE), MeiraGTx (MGTX), uniQure (QURE), Regenxbio (RGNX), Novavax (NVAX) and Lexeo Therapeutics (LXEO).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AZN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AZN
Wall Street analysts forecast AZN stock price to rise
14 Analyst Rating
13 Buy
0 Hold
1 Sell
Strong Buy
Current: 179.710
Low
157.61
Averages
213.64
High
252.18
Current: 179.710
Low
157.61
Averages
213.64
High
252.18
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AstraZeneca's Kidney Cancer Treatment Shows Progress
- Clinical Trial Results: AstraZeneca's Imfinzi combined with Imjudo, Lenvima, and TACE demonstrated significant improvement in progression-free survival compared to TACE alone, with a median progression-free survival of 13 months for the STRIDE regimen versus 9.8 months for TACE, indicating the efficacy of the new treatment.
- Risk Reduction: The interim analysis revealed that the STRIDE regimen combined with Lenvima and TACE led to a 30% reduction in the risk of disease progression or death compared to TACE alone, providing a more effective treatment option for kidney cancer patients and potentially changing clinical treatment standards.
- Survival Rate Trend: A positive trend was observed in overall survival as a secondary endpoint with STRIDE plus Lenvima and TACE compared to TACE alone, further supporting the potential advantages of this combination therapy.
- Market Outlook: AstraZeneca's innovative treatment options in the kidney cancer space not only enhance the competitiveness of its product portfolio but may also drive future revenue growth, particularly in the expanding kidney cancer treatment market.
See More
AIM ImmunoTech Hits Key Enrollment Milestone in Pancreatic Cancer Trial
- Enrollment Milestone Achieved: AIM ImmunoTech announced the completion of final patient enrollment in its pancreatic cancer trial ahead of schedule, resulting in a nearly 42% surge in stock price during Monday's opening trade, reflecting strong market confidence in its clinical progress.
- Clinical Trial Advancement: The company is continuing its Phase 3 trial planning while expanding its global regulatory and intellectual property footprint, which is expected to lay a solid foundation for the late-stage development of Ampligen and enhance its market competitiveness.
- Positive Clinical Data Support: The planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study, indicating Ampligen's potential in pancreatic cancer treatment, with over 100 patients treated, accumulating valuable clinical experience.
- Future Development Outlook: AIM's CEO stated that the completion of Ampligen dosing is expected by December 2026, when the Clinical Benefit Rate (CBR) will be evaluated, marking a significant value-inflection point for the company and further attracting investor interest.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
AstraZeneca's IMFINZI Approved by FDA for Bladder Cancer Treatment
- FDA Approval for New Therapy: AstraZeneca's IMFINZI (durvalumab) in combination with BCG has received FDA approval, marking the first new therapy for BCG-naïve high-risk non-muscle-invasive bladder cancer patients in over 30 years, representing a significant advancement in treatment options.
- Significant Clinical Trial Results: The Phase 3 POTOMAC trial demonstrated that the IMFINZI plus BCG regimen resulted in a statistically significant 32% reduction in the risk of high-risk disease recurrence or death compared to BCG alone, thereby enhancing patient survival expectations.
- Substantial Market Potential: It is estimated that over 31,000 high-risk NMIBC patients in the U.S. will be treated in 2024, and the approval of IMFINZI provides a new treatment option that could change the standard of care in this patient population.
- International Expansion Plans: AstraZeneca is pursuing regulatory submissions in the EU and Japan based on the POTOMAC trial results, indicating a strategic intent to expand its global market presence and further solidify its leadership in the biopharmaceutical sector.
See More
IMFINZI Approved for High-Risk Bladder Cancer Treatment
- Clinical Trial Results: The POTOMAC Phase III trial demonstrated that adding IMFINZI to BCG therapy reduces the risk of recurrence, progression, or death by 32% in high-risk bladder cancer patients, marking a significant advancement in treatment options for this patient population.
- FDA Approval: The FDA's approval of IMFINZI in combination with BCG represents the first new therapy for BCG-naïve high-risk non-muscle-invasive bladder cancer patients in over 30 years, which is expected to significantly improve patient survival rates and quality of life.
- Market Demand: In 2024, over 31,000 patients in the US were treated for high-risk non-muscle-invasive bladder cancer, and the approval of IMFINZI is poised to meet the urgent need for new therapies in this large patient population, potentially driving growth for the company in the oncology market.
- Long-Term Follow-Up Data: With a median follow-up of over five years, the IMFINZI plus BCG regimen has shown sustained disease-free survival benefits, further solidifying its position in the treatment of high-risk bladder cancer and potentially leading to a shift in standard care practices.
See More
AstraZeneca's Imfinzi Approved by FDA for Bladder Cancer
- FDA Approval: AstraZeneca's Imfinzi (durvalumab) has received FDA approval for Bacillus Calmette-Guérin-naïve, high-risk non-muscle-invasive bladder cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Results: The approval is based on the phase III POTOMAC trial, which demonstrated a 32% reduction in the risk of high-risk disease recurrence or death with the Imfinzi regimen compared to BCG induction and maintenance alone, highlighting its clinical efficacy.
- International Applications: AstraZeneca has submitted applications to regulators in the European Union and Japan based on the POTOMAC data, aiming to expand Imfinzi's market potential and enhance its competitive position globally.
- Financial Outlook: With the approval of Imfinzi, AstraZeneca is expected to see revenue growth in upcoming earnings reports, particularly in the oncology sector, further solidifying its attractiveness as a long-term investment.
See More
AstraZeneca's Kidney Cancer Treatment Shows Progress
- Clinical Trial Results: AstraZeneca's Imfinzi combined with Imjudo, Lenvima, and TACE demonstrated significant improvement in progression-free survival compared to TACE alone, with a median progression-free survival of 13 months for the STRIDE regimen versus 9.8 months for TACE, indicating the efficacy of the new treatment.
- Risk Reduction: The interim analysis revealed that the STRIDE regimen combined with Lenvima and TACE led to a 30% reduction in the risk of disease progression or death compared to TACE alone, providing a more effective treatment option for kidney cancer patients and potentially changing clinical treatment standards.
- Survival Rate Trend: A positive trend was observed in overall survival as a secondary endpoint with STRIDE plus Lenvima and TACE compared to TACE alone, further supporting the potential advantages of this combination therapy.
- Market Outlook: AstraZeneca's innovative treatment options in the kidney cancer space not only enhance the competitiveness of its product portfolio but may also drive future revenue growth, particularly in the expanding kidney cancer treatment market.
See More
AIM ImmunoTech Hits Key Enrollment Milestone in Pancreatic Cancer Trial
- Enrollment Milestone Achieved: AIM ImmunoTech announced the completion of final patient enrollment in its pancreatic cancer trial ahead of schedule, resulting in a nearly 42% surge in stock price during Monday's opening trade, reflecting strong market confidence in its clinical progress.
- Clinical Trial Advancement: The company is continuing its Phase 3 trial planning while expanding its global regulatory and intellectual property footprint, which is expected to lay a solid foundation for the late-stage development of Ampligen and enhance its market competitiveness.
- Positive Clinical Data Support: The planned Phase 3 program is backed by data from a Dutch Named Patient Program and encouraging results from the ongoing DURIPANC study, indicating Ampligen's potential in pancreatic cancer treatment, with over 100 patients treated, accumulating valuable clinical experience.
- Future Development Outlook: AIM's CEO stated that the completion of Ampligen dosing is expected by December 2026, when the Clinical Benefit Rate (CBR) will be evaluated, marking a significant value-inflection point for the company and further attracting investor interest.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
AstraZeneca's IMFINZI Approved by FDA for Bladder Cancer Treatment
- FDA Approval for New Therapy: AstraZeneca's IMFINZI (durvalumab) in combination with BCG has received FDA approval, marking the first new therapy for BCG-naïve high-risk non-muscle-invasive bladder cancer patients in over 30 years, representing a significant advancement in treatment options.
- Significant Clinical Trial Results: The Phase 3 POTOMAC trial demonstrated that the IMFINZI plus BCG regimen resulted in a statistically significant 32% reduction in the risk of high-risk disease recurrence or death compared to BCG alone, thereby enhancing patient survival expectations.
- Substantial Market Potential: It is estimated that over 31,000 high-risk NMIBC patients in the U.S. will be treated in 2024, and the approval of IMFINZI provides a new treatment option that could change the standard of care in this patient population.
- International Expansion Plans: AstraZeneca is pursuing regulatory submissions in the EU and Japan based on the POTOMAC trial results, indicating a strategic intent to expand its global market presence and further solidify its leadership in the biopharmaceutical sector.
See More
IMFINZI Approved for High-Risk Bladder Cancer Treatment
- Clinical Trial Results: The POTOMAC Phase III trial demonstrated that adding IMFINZI to BCG therapy reduces the risk of recurrence, progression, or death by 32% in high-risk bladder cancer patients, marking a significant advancement in treatment options for this patient population.
- FDA Approval: The FDA's approval of IMFINZI in combination with BCG represents the first new therapy for BCG-naïve high-risk non-muscle-invasive bladder cancer patients in over 30 years, which is expected to significantly improve patient survival rates and quality of life.
- Market Demand: In 2024, over 31,000 patients in the US were treated for high-risk non-muscle-invasive bladder cancer, and the approval of IMFINZI is poised to meet the urgent need for new therapies in this large patient population, potentially driving growth for the company in the oncology market.
- Long-Term Follow-Up Data: With a median follow-up of over five years, the IMFINZI plus BCG regimen has shown sustained disease-free survival benefits, further solidifying its position in the treatment of high-risk bladder cancer and potentially leading to a shift in standard care practices.
See More
AstraZeneca's Imfinzi Approved by FDA for Bladder Cancer
- FDA Approval: AstraZeneca's Imfinzi (durvalumab) has received FDA approval for Bacillus Calmette-Guérin-naïve, high-risk non-muscle-invasive bladder cancer, marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Results: The approval is based on the phase III POTOMAC trial, which demonstrated a 32% reduction in the risk of high-risk disease recurrence or death with the Imfinzi regimen compared to BCG induction and maintenance alone, highlighting its clinical efficacy.
- International Applications: AstraZeneca has submitted applications to regulators in the European Union and Japan based on the POTOMAC data, aiming to expand Imfinzi's market potential and enhance its competitive position globally.
- Financial Outlook: With the approval of Imfinzi, AstraZeneca is expected to see revenue growth in upcoming earnings reports, particularly in the oncology sector, further solidifying its attractiveness as a long-term investment.
See More
